Literature DB >> 20858137

α-Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine trafficking.

Michael J Passineau1, Timothy Fahrenholz, Laurie Machen, Lee Zourelias, Katherine Nega, Rachel Paul, Mary J MacDougall, Olga Mamaeva, Richard Steet, Jarrod Barnes, H M Kingston, Raymond L Benza.   

Abstract

Fabry disease is caused by an X-linked deficiency of the lysosomal enzyme α-galactosidase A (GLA) and has been treated successfully with enzyme replacement therapy (ERT). Gene therapy has been proposed as an alternative to ERT due to the presumed advantages of continuous, endogenous production of the therapeutic enzyme. GLA production in the liver and its therapeutic efficacy in the Fabry mouse have been demonstrated previously with various viral vector systems. In consideration of the potential advantages of using the salivary glands as endogenous GLA biosynthesis sites, we explored the feasibility of this approach in the Fabry mouse. GLA -/0 or -/- mice received an adenoviral vector (2 × 10(10) or 1 × 10(9) viral particles) expressing GLA to the right submandibular gland via oral cannulation of the submandibular duct. Four days later, animals were sacrificed; saliva, plasma, kidney, liver, and brain were collected and assayed using ELISA, Western blot, and a GLA enzymatic activity assay using both traditional fluorescence methods and isotope dilution mass spectrometry by following the U.S. EPA Method 6800. GLA activity was significantly elevated in the serum and liver of both treatment groups, and improvement in the kidney was marginally significant (P < 0.069) in the high-dose group. Notably, we found that liver and salivary gland produce different glycoforms of the GLA transgene. Only small numbers of adenoviral genomes were observed in the livers of treated animals, but in four of 14 in the high-dose groups, liver levels of adenovirus exceeded 20 copies/μg, indicating that the sequestration in the salivary gland was imperfect at high doses. Taken together, these results indicate that the salivary gland-based gene therapy for Fabry disease is promising, and further studies with advanced viral vector gene delivery systems (e.g., adeno-associated virus) for long-term treatment appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20858137      PMCID: PMC3057212          DOI: 10.1089/hum.2010.069

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  36 in total

Review 1.  Lysosomal storage diseases.

Authors:  E F Neufeld
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

Review 2.  The endocrine secretion of mammalian digestive enzymes by exocrine glands.

Authors:  L Isenman; C Liebow; S Rothman
Journal:  Am J Physiol       Date:  1999-02

Review 3.  Intracellular transport and secretion of salivary proteins.

Authors:  D Castle; A Castle
Journal:  Crit Rev Oral Biol Med       Date:  1998

Review 4.  Lysosomal storage diseases.

Authors:  V Gieselmann
Journal:  Biochim Biophys Acta       Date:  1995-04-24

5.  Purification and properties of human alpha-galactosidases.

Authors:  E Beutler; W Kuhl
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

6.  Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.

Authors:  R J Ziegler; N S Yew; C Li; M Cherry; P Berthelette; H Romanczuk; Y A Ioannou; K M Zeidner; R J Desnick; S H Cheng
Journal:  Hum Gene Ther       Date:  1999-07-01       Impact factor: 5.695

7.  Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.

Authors:  J A Medin; M Tudor; R Simovitch; J M Quirk; S Jacobson; G J Murray; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.

Authors:  T Takenaka; G Qin; R O Brady; J A Medin
Journal:  Hum Gene Ther       Date:  1999-08-10       Impact factor: 5.695

9.  alpha-Galactosidase A deficient mice: a model of Fabry disease.

Authors:  T Ohshima; G J Murray; W D Swaim; G Longenecker; J M Quirk; C O Cardarelli; Y Sugimoto; I Pastan; M M Gottesman; R O Brady; A B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

10.  Fabry's disease: alpha-galactosidase deficiency.

Authors:  J A Kint
Journal:  Science       Date:  1970-02-27       Impact factor: 47.728

View more
  10 in total

1.  An AAV2/5 vector enhances safety of gene transfer to the mouse salivary gland.

Authors:  R N Geguchadze; L Machen; L Zourelias; P H Gallo; M J Passineau
Journal:  J Dent Res       Date:  2012-02-03       Impact factor: 6.116

2.  Activation of the Innate Immune System by Treponema denticola Periplasmic Flagella through Toll-Like Receptor 2.

Authors:  John Ruby; Michael Martin; Michael J Passineau; Valentina Godovikova; J Christopher Fenno; Hui Wu
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

3.  A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.

Authors:  Changyu Zheng; Ana P Cotrim; Nikolay Nikolov; Fumi Mineshiba; William Swaim; Bruce J Baum
Journal:  Hum Gene Ther Methods       Date:  2012-07-20       Impact factor: 2.396

4.  In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy.

Authors:  Zhimin Wang; Raymond L Benza; Lee Zourelias; Angela Sanguino; Ramaz Geguchadze; Kelly J Shields; Changgong Wu; Kristin B Highland; Michael J Passineau
Journal:  Hum Gene Ther       Date:  2017-08       Impact factor: 5.695

Review 5.  Advances in salivary gland gene therapy - oral and systemic implications.

Authors:  Bruce J Baum; Ilias Alevizos; John A Chiorini; Ana P Cotrim; Changyu Zheng
Journal:  Expert Opin Biol Ther       Date:  2015-07-06       Impact factor: 4.388

Review 6.  Gene delivery in salivary glands: from the bench to the clinic.

Authors:  Yuval Samuni; Bruce J Baum
Journal:  Biochim Biophys Acta       Date:  2011-07-06

Review 7.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

8.  Gene therapy.

Authors:  B J Baum
Journal:  Oral Dis       Date:  2013-12-26       Impact factor: 3.511

Review 9.  Glucagon-like peptide-1 gene therapy.

Authors:  Anne M Rowzee; Niamh X Cawley; John A Chiorini; Giovanni Di Pasquale
Journal:  Exp Diabetes Res       Date:  2011-06-20

10.  IL-17 sequestration via salivary gland gene therapy in a mouse model of Sjogren's syndrome suppresses disease-associated expression of the putative autoantigen Klk1b22.

Authors:  Changgong Wu; Zhimin Wang; Lee Zourelias; Hiteshi Thakker; Michael J Passineau
Journal:  Arthritis Res Ther       Date:  2015-08-06       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.